Associated Papers
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro.
Yang Z et al.
Acs Omega, 2025
A mutation in CCDC91, Homo sapiens coiled-coil domain containing 91 protein, cause autosomal-dominant acrokeratoelastoidosis.
Zhu Y et al.
European Journal of Human Genetics : Ejhg, 2024
Gene polymorphisms and thyroid hormone signaling: implication for the treatment of hypothyroidism.
Penna GC et al.
Endocrine, 2024
Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer.
Deng F et al.
Basic & Clinical Pharmacology & Toxicology, 2023
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
Nies AT et al.
Pharmacology & Therapeutics, 2022
Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry.
Bateman NW et al.
Iscience, 2022
Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.
Vanwong N et al.
Pharmacogenomics and Personalized Medicine, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Mohammadi F et al.
Laboratory Medicine, 2021
Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.
van Eijk M et al.
The Pharmacogenomics Journal, 2021
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Hertz DL
Expert Opinion on Drug Metabolism & Toxicology, 2021
Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report.
Dagli-Hernandez C et al.
Annals of Translational Medicine, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions.
Calderon-Ospina CA et al.
Pharmacogenomics and Personalized Medicine, 2020
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
Yang F et al.
Scientific Reports, 2018
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW et al.
Clinical Pharmacology and Therapeutics, 2018
Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population.
Cai LL et al.
Scientific Reports, 2017
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y et al.
Cancer Chemotherapy and Pharmacology, 2017
SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry.
Evangeli L et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.
Tounsi N et al.
Pharmacology, 2017
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
Picard N et al.
Therapeutic Drug Monitoring, 2016
Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
Park HS et al.
Pharmacogenetics and Genomics, 2016
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.
Lu C et al.
Cold Spring Harbor Molecular Case Studies, 2016
Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
de Lima LT et al.
Hematology (amsterdam, Netherlands), 2015
Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.
Sato H et al.
Journal of Human Genetics, 2015
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
Meyer zu Schwabedissen HE et al.
Bmc Research Notes, 2014
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.
Aminkeng F et al.
The Pharmacogenomics Journal, 2014
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM et al.
Methods in Molecular Biology (clifton, N.j.), 2014
Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N et al.
Prostate Cancer and Prostatic Diseases, 2013
Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM et al.
Hematology (amsterdam, Netherlands), 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
Sortica Vde A et al.
Basic & Clinical Pharmacology & Toxicology, 2012
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC et al.
British Journal of Clinical Pharmacology, 2012
Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population.
Chae YJ et al.
Journal of Pharmaceutical Sciences, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2011
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK et al.
The Pharmacogenomics Journal, 2011
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A et al.
Basic & Clinical Pharmacology & Toxicology, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Pharmacogenetics of membrane transporters: an update on current approaches.
Sissung TM et al.
Molecular Biotechnology, 2010
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM et al.
Clinical Pharmacology and Therapeutics, 2008